REPORT ID 2778

EMEA (Europe, Middle East and Africa) Traumatic Brain Injury Therapeutics Market Report 2017

Publish Date
11-Dec-17
Pages
110
Format
Electronic (PDF)

In this report, the EMEA Traumatic Brain Injury Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Traumatic Brain Injury Therapeutics for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Traumatic Brain Injury Therapeutics market competition by top manufacturers/players, with Traumatic Brain Injury Therapeutics sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    SFC Fluidics LLC
    Banayan Biomarkers Inc.
    BHR Pharma LLC
    Cerora Inc.
    ElMindA Ltd.
    Grace Laboratories LLC
    KeyNeurotek Pharmaceuticals AG
    Luoxis Diagnostics
    Neuro Assessment Systems
    Neurovive Pharmaceuticals AB
    Oxygen Biotherapeutics Inc.
    Phlogistix LLC
    Neurohealing Pharmaceuticals
    Neuren Pharmaceuticals Ltd.
    Remedy Pharmaceuticals Inc.
    Biodirection Inc.
    Brainscope Company Inc.
    TEVA Pharmaceutical Industries Ltd.
    Vasopharm

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Acetylcholinesterase Inhibitors
    Erythropoietin
    Growth Hormone
    Stem Cells
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Focal TBI
    Open TBI
    Closed TBI
    Diffuse TBI
    Primary TBI
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Traumatic Brain Injury Therapeutics Market Report 2017
1 Traumatic Brain Injury Therapeutics Overview
    1.1 Product Overview and Scope of Traumatic Brain Injury Therapeutics
    1.2 Classification of Traumatic Brain Injury Therapeutics
        1.2.1 EMEA Traumatic Brain Injury Therapeutics Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Traumatic Brain Injury Therapeutics Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Acetylcholinesterase Inhibitors
        1.2.4 Erythropoietin
        1.2.5 Growth Hormone
        1.2.6 Stem Cells
        1.2.7 Others
    1.3 EMEA Traumatic Brain Injury Therapeutics Market by Application/End Users
        1.3.1 EMEA Traumatic Brain Injury Therapeutics Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Focal TBI
        1.3.3 Open TBI
        1.3.4 Closed TBI
        1.3.5 Diffuse TBI
        1.3.6 Primary TBI
        1.3.7 Others
    1.4 EMEA Traumatic Brain Injury Therapeutics Market by Region
        1.4.1 EMEA Traumatic Brain Injury Therapeutics Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Traumatic Brain Injury Therapeutics (2012-2022)
        1.5.1 EMEA Traumatic Brain Injury Therapeutics Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Traumatic Brain Injury Therapeutics Revenue and Growth Rate (2012-2022)

2 EMEA Traumatic Brain Injury Therapeutics Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Traumatic Brain Injury Therapeutics Market Competition by Players/Manufacturers
        2.1.1 EMEA Traumatic Brain Injury Therapeutics Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Traumatic Brain Injury Therapeutics Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Traumatic Brain Injury Therapeutics Sale Price by Players (2012-2017)
    2.2 EMEA Traumatic Brain Injury Therapeutics (Volume and Value) by Type/Product Category
        2.2.1 EMEA Traumatic Brain Injury Therapeutics Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Traumatic Brain Injury Therapeutics Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Traumatic Brain Injury Therapeutics Sale Price by Type (2012-2017)
    2.3 EMEA Traumatic Brain Injury Therapeutics (Volume) by Application
    2.4 EMEA Traumatic Brain Injury Therapeutics (Volume and Value) by Region
        2.4.1 EMEA Traumatic Brain Injury Therapeutics Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Traumatic Brain Injury Therapeutics Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Traumatic Brain Injury Therapeutics Sales Price by Region (2012-2017)

3 Europe Traumatic Brain Injury Therapeutics (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Traumatic Brain Injury Therapeutics Sales and Value (2012-2017)
        3.1.1 Europe Traumatic Brain Injury Therapeutics Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Traumatic Brain Injury Therapeutics Revenue and Growth Rate (2012-2017)
    3.2 Europe Traumatic Brain Injury Therapeutics Sales and Market Share by Type
    3.3 Europe Traumatic Brain Injury Therapeutics Sales and Market Share by Application
    3.4 Europe Traumatic Brain Injury Therapeutics Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Traumatic Brain Injury Therapeutics Sales Volume by Countries (2012-2017)
        3.4.2 Europe Traumatic Brain Injury Therapeutics Revenue by Countries (2012-2017)
        3.4.3 Germany Traumatic Brain Injury Therapeutics Sales and Growth Rate (2012-2017)
        3.4.4 France Traumatic Brain Injury Therapeutics Sales and Growth Rate (2012-2017)
        3.4.5 UK Traumatic Brain Injury Therapeutics Sales and Growth Rate (2012-2017)
        3.4.6 Russia Traumatic Brain Injury Therapeutics Sales and Growth Rate (2012-2017)
        3.4.7 Italy Traumatic Brain Injury Therapeutics Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Traumatic Brain Injury Therapeutics Sales and Growth Rate (2012-2017)

4 Middle East Traumatic Brain Injury Therapeutics (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Traumatic Brain Injury Therapeutics Sales and Value (2012-2017)
        4.1.1 Middle East Traumatic Brain Injury Therapeutics Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Traumatic Brain Injury Therapeutics Revenue and Growth Rate (2012-2017)
    4.2 Middle East Traumatic Brain Injury Therapeutics Sales and Market Share by Type
    4.3 Middle East Traumatic Brain Injury Therapeutics Sales and Market Share by Application
    4.4 Middle East Traumatic Brain Injury Therapeutics Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Traumatic Brain Injury Therapeutics Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Traumatic Brain Injury Therapeutics Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Traumatic Brain Injury Therapeutics Sales and Growth Rate (2012-2017)
        4.4.4 Israel Traumatic Brain Injury Therapeutics Sales and Growth Rate (2012-2017)
        4.4.5 UAE Traumatic Brain Injury Therapeutics Sales and Growth Rate (2012-2017)
        4.4.6 Iran Traumatic Brain Injury Therapeutics Sales and Growth Rate (2012-2017)

5 Africa Traumatic Brain Injury Therapeutics (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Traumatic Brain Injury Therapeutics Sales and Value (2012-2017)
        5.1.1 Africa Traumatic Brain Injury Therapeutics Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Traumatic Brain Injury Therapeutics Revenue and Growth Rate (2012-2017)
    5.2 Africa Traumatic Brain Injury Therapeutics Sales and Market Share by Type
    5.3 Africa Traumatic Brain Injury Therapeutics Sales and Market Share by Application
    5.4 Africa Traumatic Brain Injury Therapeutics Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Traumatic Brain Injury Therapeutics Sales Volume by Countries (2012-2017)
        5.4.2 Africa Traumatic Brain Injury Therapeutics Revenue by Countries (2012-2017)
        5.4.3 South Africa Traumatic Brain Injury Therapeutics Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Traumatic Brain Injury Therapeutics Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Traumatic Brain Injury Therapeutics Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Traumatic Brain Injury Therapeutics Sales and Growth Rate (2012-2017)

6 EMEA Traumatic Brain Injury Therapeutics Manufacturers/Players Profiles and Sales Data
    6.1 SFC Fluidics LLC
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Traumatic Brain Injury Therapeutics Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 SFC Fluidics LLC Traumatic Brain Injury Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Banayan Biomarkers Inc.
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Traumatic Brain Injury Therapeutics Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Banayan Biomarkers Inc. Traumatic Brain Injury Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 BHR Pharma LLC
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Traumatic Brain Injury Therapeutics Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 BHR Pharma LLC Traumatic Brain Injury Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Cerora Inc.
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Traumatic Brain Injury Therapeutics Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Cerora Inc. Traumatic Brain Injury Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 ElMindA Ltd.
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Traumatic Brain Injury Therapeutics Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 ElMindA Ltd. Traumatic Brain Injury Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Grace Laboratories LLC
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Traumatic Brain Injury Therapeutics Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Grace Laboratories LLC Traumatic Brain Injury Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 KeyNeurotek Pharmaceuticals AG
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Traumatic Brain Injury Therapeutics Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 KeyNeurotek Pharmaceuticals AG Traumatic Brain Injury Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Luoxis Diagnostics
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Traumatic Brain Injury Therapeutics Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Luoxis Diagnostics Traumatic Brain Injury Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Neuro Assessment Systems
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Traumatic Brain Injury Therapeutics Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Neuro Assessment Systems Traumatic Brain Injury Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Neurovive Pharmaceuticals AB
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Traumatic Brain Injury Therapeutics Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Neurovive Pharmaceuticals AB Traumatic Brain Injury Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Oxygen Biotherapeutics Inc.
    6.12 Phlogistix LLC
    6.13 Neurohealing Pharmaceuticals
    6.14 Neuren Pharmaceuticals Ltd.
    6.15 Remedy Pharmaceuticals Inc.
    6.16 Biodirection Inc.
    6.17 Brainscope Company Inc.
    6.18 TEVA Pharmaceutical Industries Ltd.
    6.19 Vasopharm

7 Traumatic Brain Injury Therapeutics Manufacturing Cost Analysis
    7.1 Traumatic Brain Injury Therapeutics Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Traumatic Brain Injury Therapeutics

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Traumatic Brain Injury Therapeutics Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Traumatic Brain Injury Therapeutics Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Traumatic Brain Injury Therapeutics Market Forecast (2017-2022)
    11.1 EMEA Traumatic Brain Injury Therapeutics Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Traumatic Brain Injury Therapeutics Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Traumatic Brain Injury Therapeutics Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Traumatic Brain Injury Therapeutics Price and Trend Forecast (2017-2022)
    11.2 EMEA Traumatic Brain Injury Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Traumatic Brain Injury Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Traumatic Brain Injury Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Traumatic Brain Injury Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Traumatic Brain Injury Therapeutics Sales Forecast by Type (2017-2022)
    11.7 EMEA Traumatic Brain Injury Therapeutics Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer